Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with diabetes mellitus

Effects of sodium-glucose co-transporter 2 inhibitor on metabolic parameters in patients with diabetes mellitus - Effects of SGLT2 inhibitor on metabolic parameters in patients with diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021584

Enrollment

150

Registered

2016-03-23

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Any one of SGLT2 inhibitors (luseogliflozin (2.5 mg q.d.) , dapagliflozin (5 mg q.d.), tofogliflozin (20 mg q.d.), empagliflozin (10 mg q.d.), or canagliflozin (100 mg q.d.)) is administered for 6 mo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients. Obtained written informed consent from the patients before participation.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Lipid-metabolic parameters: serum total cholesterol, HDL and LDL cholesterol, and triglyceride levels Hepatic function parameters: serum AST, ALT, and gamma-GTP levels Genital infection (female): intravaginal bacteria and fungi These parameters are compared before and 6 mo after the administration of SGLT2 inhibitor.	—

Secondary

Measure	Time frame
Visceral fat area, basal metabolic rate, and serum insulin and adiponectin levels	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

info@tonyo.jp052-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026